An ultra-sensitive method to detect mutations in human RAS templates

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• RAS family small GTPases are frequently mutated in human cancers, with specific hotspot mutations driving oncogenesis.
• Oncogenic RAS mutations are often early events in tumorigenesis, making their detection crucial for understanding cancer origins and early detection.
• Previous work adapted a Maximum Depth Sequencing (MDS) assay for murine Kras, demonstrating its ability to detect mutations shortly after carcinogen exposure.

Purpose of the Study:

• To adapt and detail an ultra-sensitive Maximum Depth Sequencing (MDS) assay for detecting mutations in the human KRAS gene.
• To achieve a high analytic sensitivity for detecting oncogenic KRAS mutations, enabling the identification of rare mutational events.
• To establish a foundation for applying this sensitive assay to other RAS family genes for comprehensive cancer mutation analysis.

Main Methods:

• Adaptation of the microbial ultra-sensitive Maximum Depth Sequencing (MDS) assay for a human KRAS sequence.
• Optimization of the assay to achieve an analytic sensitivity of one mutation in a million independently barcoded templates.
• Validation of the assay's capability to detect oncogenic mutations in human KRAS.

Main Results:

• The humanized MDS assay successfully detects mutations in a human KRAS sequence.
• The assay demonstrates an analytic sensitivity of one in a million independently barcoded templates for KRAS mutations.
• This high sensitivity allows for the detection of rare oncogenic mutations, crucial for early cancer detection.

Conclusions:

• The adapted MDS assay provides an ultra-sensitive method for detecting oncogenic mutations in human KRAS.
• This technology can be valuable for early cancer detection and for studying the initiating events of RAS-driven cancers.
• The assay is adaptable for detecting mutations in other RAS family genes, offering a versatile tool for cancer research.